title: Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity".
authors.affiliation: San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, CA.
authors.forename: John R
authors.initials: JR
authors.lastname: Teerlink
authors.affiliation: Cytokinetics, Inc, San Francisco, CA.
authors.forename: Fady I
authors.initials: FI
authors.lastname: Malik
authors.affiliation: The Johns Hopkins University Medical Institutions, Baltimore, MD.
authors.forename: David A
authors.initials: DA
authors.lastname: Kass
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D020536:Enzyme Activators / Q000494:pharmacology*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D008297:Male; D009203:Myocardial Infarction / Q000150:complications*; D009206:Myocardium / Q000201:enzymology*; D009218:Myosins / Q000378:metabolism*; D010101:Oxygen Consumption / Q000187:drug effects*; D014508:Urea / Q000031:analogs & derivatives*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D002316:Cardiotonic Agents; D020536:Enzyme Activators; D014508:Urea; D009218:Myosins